Mylan News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

25.10.17	CLSD Progressing With TYBEE, SNY In Legal Spat With MYL, TBPH On Watch (RTTNews)
24.10.17	Sanofi Files Suit Against Mylan To Defend Patent Rights - Quick Facts (RTTNews)
17.10.17	Mylan to Report Third Quarter 2017 Financial Results on Nov. 6, 2017 (PR Newswire)
17.10.17	Mylan Invalidates Allergan's Patents on Restasis® (PR Newswire)
05.10.17	Mylan, in Partnership with Synthon, Receives Marketing Authorization Approval in Europe for First Generic for Copaxone® 40 mg/mL (PR Newswire)
05.10.17	Mylan Launches First AP-rated Generic Avelox® Injection (PR Newswire)
05.10.17	Mylan Confirms U.S. Launch of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and Generic for Copaxone® 20 mg/mL Once-Daily (PR Newswire)
04.10.17	Mylan Holding On To Substantial Gain In Afternoon Trading (RTTNews)
04.10.17	Mylan Provides Support for U.S. Disaster-Relief Efforts (PR Newswire)
04.10.17	Gilead To License Generic Production Of Bictegravir To MPP & Four Manufacturers (RTTNews)
04.10.17	CLSN Is Hot & Newsy, CTMX Soars On AMGN Deal, SUNFISH Fails To Help PTCT Shine (RTTNews)
04.10.17	Mylan : FDA Approves First Generic For Copaxone 40 Mg/mL 3-Times-a-Week (RTTNews)
04.10.17	Mylan Announces U.S. FDA Approval of First Generic for Copaxone® 40 mg/mL 3-Times-a-Week and May Be Eligible for 180-Day Exclusivity (PR Newswire)
02.10.17	Mylan Launches Generic Cancidas® for Injection (PR Newswire)
29.09.17	Mylan Launches Generic Gleevec® Tablets (PR Newswire)
29.09.17	Biotech Stocks Facing FDA Decision In October (RTTNews)
25.09.17	Indivior In Deal To Settle SUBOXONE Patent Infringement Case With Mylan (RTTNews)
19.09.17	TIBCO Connected Intelligence Cloud Equips Companies for Digital Transformation (PR Newswire)
18.09.17	Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Horizon Pharma, Mylan, and Neurocrine Biosciences (PR Newswire)
15.09.17	Indivior Unit Files Lawsuits In U.S. To Protect SUBOXONE Film Patent (RTTNews)
14.09.17	Mylan Expands Women's Healthcare Portfolio with Launch of Generic Minastrin® 24 FE Tablets (PR Newswire)
13.09.17	Mylan Names Dennis Zeleny as Chief Human Relations Officer (PR Newswire)
08.09.17	FDA Warns Of Manufacturing Violations To EpiPen Plant (RTTNews)
29.08.17	Biotech Stocks Facing FDA Decision In September (RTTNews)
24.08.17	Mylan Granted License To Prioritize Access To Deltyba In South Africa, India (RTTNews)
24.08.17	Otsuka and Mylan Announce License Agreement to Commercialize Delamanid (Deltyba™) for Multidrug-Resistant Tuberculosis (MDR-TB) in High-Burden Countries (PR Newswire)
17.08.17	Mylan Finalizes Settlement Agreement On EpiPen Auto-Injector (RTTNews)
14.08.17	Breakfast Technical Briefing on Generic Drugs Stocks -- Horizon Pharma, Mylan, Neurocrine Biosciences, and Rigel Pharma (PR Newswire)
10.08.17	Mylan Advances Access in the Fight Against HIV with the Launch of Three Generic Antiretroviral Medicines in Canada (PR Newswire)
09.08.17	Mylan Cuts 2017 Outlook; Stock Down (RTTNews)
09.08.17	Mylan N.V. Profit Retreats 0% In Q2 (RTTNews)
09.08.17	Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance (PR Newswire)
08.08.17	Mylan Pharma Launches Avonza In India (RTTNews)
08.08.17	Mylan Launches Avonza™ in India (PR Newswire)
07.08.17	Mylan Gets FDA's Tentative Approval For "TLD" Under PEPFAR For HIV/AIDS (RTTNews)
26.07.17	Mylan Receives WHO Prequalification for Generic Sovaldi® (PR Newswire)
20.07.17	SRPT Soars On Q2 Results & Outlook, AERI's Mercury-1 Does An Encore, ALIM Abuzz (RTTNews)
19.07.17	Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)
19.07.17	Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) (PR Newswire)
19.07.17	Mylan to Report Second Quarter 2017 Financial Results on Aug. 9, 2017 (PR Newswire)
14.07.17	FDA Panel Backs 2 Biosimilars, ALDR Abuzz, MDXG Q2 Revenue Grows 33% (RTTNews)
14.07.17	FDA Panel Recommends Approval Of Mylan And Biocon's Biosimilar Trastuzumab (RTTNews)
13.07.17	FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab (PR Newswire)
13.07.17	NVS Gets Thumbs Up, Two Biosimilar Candidates To Face FDA Panel, VKTX On Track (RTTNews)
10.07.17	Technical Snapshots for These Generic Drugs Stocks -- Horizon Pharma, Mylan, Neurocrine Biosciences, and Rigel Pharma (PR Newswire)
29.06.17	Biotech Stocks Facing FDA Decision In July (RTTNews)
10.06.17	Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association's 77th Scientific Sessions (PR Newswire)
07.06.17	Mylan to Present at Goldman Sachs 38th Annual Global Healthcare Conference (PR Newswire)
02.06.17	Mylan Launches Generic Version Of Teva's Azilect Tablets - Quick Facts (RTTNews)
02.06.17	Mylan Launches Generic Azilect® Tablets (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Novartis	92.75	0.89 %	K V
Nestle	76.36	0.69 %	K V
Swisscom	506.50	0.50 %	K V
Alcon	78.00	0.49 %	K V
Roche Hldg G	252.50	0.44 %	K V
CieFinRichemont	121.90	-0.37 %	K V
Sika	226.60	-0.87 %	K V
ABB	49.02	-1.05 %	K V
Lonza Grp	517.00	-2.64 %	K V
Logitech Intl	70.06	-2.67 %	K V

mehr

20:03		Dow Jones aktuell: Dow Jones legt nachmittags den Rückwärtsgang ein
18:01		Schwacher Wochentag in New York: Dow Jones verliert am Mittwochmittag
17:58		STOXX 50 aktuell: STOXX 50 zeigt sich zum Handelsende schwächer
17:58		Starker Wochentag in Zürich: SMI zum Handelsende freundlich
17:58		Schwacher Handel: SLI zum Handelsende im Minus
17:51		Novartis-Aktie höher: EU-Zulassung für Kisqali - Funktion des Schweizer Länderpräsidenten gestrichen
15:58		Minuszeichen in Europa: STOXX 50 legt am Mittwochnachmittag den Rückwärtsgang ein
15:58		Schwache Performance in Zürich: SLI nachmittags im Minus

20:03

Dow Jones aktuell: Dow Jones legt nachmittags den Rückwärtsgang ein

18:01

Schwacher Wochentag in New York: Dow Jones verliert am Mittwochmittag

17:58

STOXX 50 aktuell: STOXX 50 zeigt sich zum Handelsende schwächer

17:58

Starker Wochentag in Zürich: SMI zum Handelsende freundlich

17:58

Schwacher Handel: SLI zum Handelsende im Minus

17:51

Novartis-Aktie höher: EU-Zulassung für Kisqali - Funktion des Schweizer Länderpräsidenten gestrichen